FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 446 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL September 21, 2021 Advancing Patient Care Through Focused Innovation April 16, 2018 Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan December 15, 2020 Load more HOT NEWS As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Cancer in My Community: Expanding Genetic Testing in Thailand Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and...
